
Zymeworks Inc (ZYME) Stock Forecast & Price Target
Zymeworks Inc (ZYME) Analyst Ratings
Bulls say
Zymeworks is a clinical-stage biopharmaceutical company with a diversified pipeline and promising clinical candidate, zanidatamab, targeting HER2-expressing tumors. With a discounted cash flow analysis, a target firm value of ~$3.8B was calculated, and the management has a positive outlook on zanidatamab's approval in multiple indications. Risks to the positive outlook include clinical trial failures, competition, regulatory risks, and sector risks. However, with a strong partnership with Jazz Pharma and a promising pipeline, Zymeworks' stock has a potential upside in the future.
Bears say
Zymeworks is a biopharmaceutical company that has a negative outlook, mainly due to limited direct insight into Johnson & Johnson's decision to expand Phase 3 enrollment for Zymeworks' pasritamig, and the company's dependence on clinical trials for its valuation. Additionally, Zymeworks faces marketing, biotech sector, clinical trial, and stock price volatility risks. Financially, the company may struggle to create incremental shareholder value in the near term due to limited pipeline options. Based on a DCF through 2034, Zymeworks has a target price of $17, assuming a 9% WACC and 0.5% terminal growth rate.
This aggregate rating is based on analysts' research of Zymeworks Inc and is not a guaranteed prediction by Public.com or investment advice.
Zymeworks Inc (ZYME) Analyst Forecast & Price Prediction
Start investing in Zymeworks Inc (ZYME)
Order type
Buy in
Order amount
Est. shares
0 shares